News

Mr Macdonald most recently served as president and CEO at Nanomix. He also served as president and COO of Nichols Institute Diagnostics, a division of Quest Diagnostics and

Two doses of AZ-104, 2.5 and 5mg, met the primary endpoint of two-hour pain-relief compared to placebo. The company has said that statistically significant improvements in pain response

Under the terms of the agreement, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds. MicroDose will receive

The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The Mindset-01 Phase II, double-blind, placebo-controlled trial is designed to evaluate the safety

The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both

This intellectual property portfolio is complementary to Amarin’s existing lipid-based development programs including AMR101 and its targeted lipid transport technology. The transaction consideration comprises an upfront fee to

ARRY-797 achieved its primary and secondary endpoints for analgesic efficacy and was well tolerated. Based on these results, Array is moving forward with a second Phase II acute

According to the company, Acuity Spiral lead is seventh US or European regulatory approval in the past nine weeks. The Acuity Spiral lead is pending approval by the

Beta-bsm and Gamma-bsm are extensions to company’s unique line of bone substitute material products and provide the surgeon the flexibility to adapt to specific patient needs. Beta- bsm